Oncolytics Biotech Inc ONCY

RE:RE:RE:Biotech M&A is picking back up according to BiopharmaDive

[Noteable]

November 30, 2023 - Over the last few years, pharmaceutical M&A hit record highs as larger companies turned again and again to young biotechs for innovation. Often, these deals focused on cancer, rare diseases and immune system disorders — areas of drug research that were seeing major victories in clinical trials and huge profits for treatments that made it to market. 

These deals haven’t come cheap. Such high prices have been due, at least in part, to the fact that biotechs were able to secure large amounts of funding from private investors and the public markets, in turn forcing potential buyers to offer up more money to lock down deals. 

https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

One of the peculiar facts about biotech specifically is how so much investor interest in biotech flows from M&A exits. 

Most of the M&A outcomes that happen in the world are for single product biotech companies. even in times where platform companies are ‘hot,’ a lot of the biggest M&A exits are still product-focused exits. Big pharma companies sometimes buy platforms, but much more often they buy a product and if a platform comes along, they’re happy with that.